{"DataElement":{"publicId":"3361995","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Serum HCG Measurement Diagnosis Value","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation._The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Dise_FIGO_Seru_Diag_Seru_Huma_","context":"NRG","contextVersion":"1","DataElementConcept":{"publicId":"3361992","version":"1","preferredName":"Disease or Disorder FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Serum HCG Measurement Diagnosis","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk._A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"Dise_FIGO_Seru_Diag","context":"NRG","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3361990","version":"1","preferredName":"FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms Serum HCG Measurement Diagnosis","preferredDefinition":"A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk.:A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.:The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"C99408:C73495:C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"FIGO Staging System and Modified World Health Organization [WHO] Prognostic Scoring System for Gestational Trophoblastic Neoplasms","conceptCode":"C99408","definition":"A system for defining prognosis for gestational trophoblastic neoplasia. In this system, the FIGO stage is represented by an Roman numeral, followed by the modified WHO score depicted as an Arabic numeral and separated by a colon (e.g., Stage II:4, Stage IV:9). Scores of 0-6 are considered low-risk and scores greater than 6 are considered high-risk.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Serum HCG Measurement","conceptCode":"C73495","definition":"A quantitative measurement of the amount of human chorionic gonadotropin present in a sample of serum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D395-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"ONEDATA","dateModified":"2012-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3A6-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3361994","version":"1","preferredName":"Serum Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed._The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104)_A numerical quantity measured or assigned or computed.","longName":"Seru_Huma_Valu","context":"NRG","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":"1","format":"999999.9","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3361993","version":"1","preferredName":"Serum Human Chorionic Gonadotropin Beta Subunit Value","preferredDefinition":"The clear liquid part of the blood that remains after blood cells and clotting proteins have been removed.:The beta subunit of human chorionic gonadotropin. It is used as a clinical marker to facilitate early detection of normal pregnancy and significantly contributes to the diagnosis of various pregnancy-related disorders, such as ectopic pregnancy, spontaneous abortion, hydatidiform mole, choriocarcinoma, or Trisomy 21. Further, determination of this marker is immensely helpful to guide curative intervention in testicular cancer. Other possible clinical uses includes as a marker of cancers of the bladder, pancreas, or biliary tract. (Scan J Clin Lab Invest Suppl 1993;216:97-104):A numerical quantity measured or assigned or computed.","longName":"C13325:C17479:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Serum","conceptCode":"C13325","definition":"The clear portion of the blood that remains after the removal of the blood cells and the clotting proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Choriogonadotropin Subunit Beta 3","conceptCode":"C17479","definition":"Choriogonadotropin subunit beta 3 (165 aa, ~18 kDa) is encoded by the human CGB3, CGB5, and CGB8 genes. This protein is involved in the regulation of steroid synthesis during pregnancy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3BB-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"ONEDATA","dateModified":"2012-01-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3CC-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"SBR","dateModified":"2013-08-01","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"4057943","version":"1","longName":"Disease Site","context":"NRG","ClassificationSchemeItems":[{"publicId":"4104991","version":"1","longName":"GOG-0275","context":"NRG"}]}],"AlternateNames":[{"name":"Dise_FIGO_Seru_Diag_Seru_Huma_","type":"USED_BY","context":"NRG"}],"ReferenceDocuments":[{"name":"Serum Beta-hCG (mIU/mL)","type":"Preferred Question Text","description":"Serum Beta-hCG (mIU/mL)","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B749E724-D3E0-0EC8-E040-BB89AD43503D","latestVersionIndicator":"Yes","beginDate":"2012-01-24","endDate":null,"createdBy":"REBOYJ","dateCreated":"2012-01-24","modifiedBy":"FORMBUILDER","dateModified":"2014-09-02","changeDescription":" Changed from CTEP to GOG for REBOYJ by script Thu Aug 1 14:45:44 EDT 2013","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}